Pharmaceuticals News

EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists.

Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027 ...

NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying...

SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways...

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build,...

SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions...

SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will...

New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development...

Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trialThe Company has a statistical team who are doing periodic reviews of the...

New patent allowances in South Korea, Mexico, New Zealand and the Philippines Further expand IP protection across BPD, ASD, aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Oct. 15,...